That's right, pigs. The long-term viability of the company...

That's right, pigs. The long-term viability of the company relies on a good partnering deal with big pharma, but that may not happen before the options exercise date.

In the interim, a couple of big international speculators buying in would push up the SP and get the oppies over the line. Given how thin the sell side of BIT is, it wouldn't take much cash to give the SP and oppies a big lift in price.

That's why it's good to see reports like edisons going to investors outside Australia.

You would have to think management would be doing all it could to push the company to these sorts of analysts and tip sheets, etc.

The other thing that would give the SP the required lift would be a new report from Southern Cross after the HepDart presentation.

Could be an interesting month or so,

Good luck to all.